About our Central Nervous System Diseases efforts
We are redefining mental health to enable people to thrive. We link behavior to the underlying neurobiology to develop targeted therapies that can ease the burden of these conditions, not just the symptoms. By combining traditional treatment with new and innovative approaches and technologies, we will enable those with mental health conditions to create more meaningful connections to their lives, loved ones and society.
Selection of projects in February 2024
Phase 1 studies are usually designed with an emphasis on the assessment of safety and tolerability of an investigational drug in a small group of people for the first time. It can include healthy participants or participants with the disease.
NDMA regulator
Digital Therapeutic
Phase 2 studies are usually designed to begin to evaluate the efficacy of an investigational drug in a higher number of participants with the disease, and often used to obtain dose-ranging information. Safety also continues to be assessed during this phase.
BI 1358894
Phase 3 studies are designed to confirm the data of Phase 2 studies for an investigational drug. Large numbers of participants with the disease are generally involved to obtain safety and efficacy data to evaluate the overall benefit-risk relationship of an investigational drug to provide an adequate basis for regulatory approvals. Given the size of these studies and to ensure a representative sample of patients, they are often conducted across several countries.
CT-155
Iclepertin
Indication abbreviations
MDD: Major depressive disorder
CIAS: Cognitive impairment associated with schizophrenia